Table 3.
Effects of casein hydrolysate (CH), its plastein modifiers and mixtures at three assessed dose levels on the growth proliferation of the macrophages reflected by the measured cell viability (%).
| Sample | Cell Viability at Different Dose Levels (μg/mL) | ||
|---|---|---|---|
| 25 | 50 | 100 | |
| CH | 102.5 ± 2.2 Ae | 110.2 ± 3.7 Bd | 111.7 ± 3.5 Bd |
| PCH | 111.8 ± 4.6 Aabcd | 115.2 ± 4.9 Abcd | 119.1 ± 1.8 Abc |
| PCH-Gly | 114.3 ± 6.3 Aab | 121.3 ± 5.5 Aab | 124.4 ± 2.6 Ab |
| PCH-Pro | 113.7 ± 3.9 Babc | 119.6 ± 4.2 ABabc | 122.9 ± 3.5 Ab |
| PCH-Hyp | 115.4 ± 5.6 Ba | 125.9 ± 4.1 Aa | 129.7 ± 2.2 Aa |
| CH-Gly | 103.9 ± 2.5 Bde | 112.5 ± 5.5 Abcd | 113.3 ± 4.2 Ad |
| CH-Pro | 105.6 ± 3.3 Acd | 112.1 ± 6.0 Acd | 112.7 ± 1.8 Ad |
| CH-Hyp | 106.4 ± 4.9 Bbcde | 113.7 ± 2.8 ABbcd | 114.5 ± 3.3 Acd |
PCH—the modifier of CH without exogenous amino acids; PCH-Gly (PCH-Pro or PCH-Hyp)—the modifier of CH in the presence of Gly (Pro or Hyp); CH-Gly (CH-Pro or CH-Hyp)—the mixture of CH and Gly (Pro or Hyp). Different uppercase (or lowercase) letters as superscripts after the mean values in the same row (or column) indicate that one-way ANOVA of the mean values is significantly different (p < 0.05).